PKC-epsilon inhibitors

摘要

The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

主权项

1. A method for treating a patient suffering from a disease or disorder selected from the group consisting of pain, substance abuse substance dependencies and depression, which method comprises administering to a patient an effective amount of a compound of Formula I or a salt thereof:wherein
Ar is pyridyl; Cy is selected from the group consisting of cyclohexyl, adamantyl and piperidinyl; n is 0 or −1; and R1 is selected from:with the proviso that when n is 0, then R1 is A is oxygen or sulfur; and R5, R6 and R7 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, or heterocyclyl, where the cycloalkyl or heterocyclyl group may be fused to one phenyl or pyridyl group, and where each of said alkyl, cycloalkyl, heterocyclyl, phenyl or pyridyl groups is-optionally substituted by halo, aryl, cycloalkyl, phenyl or pyridyl.